HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5787
Abstract: Immunotherapy (IO) plus tyrosine kinase inhibitor (TKI) emerged as standard first‐line therapy for advanced renal cell carcinoma (RCC). The heme Oxygenase 1 (HMOX1) pathway is involved in tumor development and treatment resistance, which may affect… read more here.
Keywords: plus tyrosine; kinase inhibitor; immunotherapy plus; tyrosine kinase ... See more keywords
Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34180
Abstract: Conditional survival estimates provide critical prognostic information for patients with advanced renal cell carcinoma (aRCC). Efficacy, safety, and conditional survival outcomes were assessed in CheckMate 214 (ClinicalTrials.gov identifier NCT02231749) with a minimum follow‐up of 5… read more here.
Keywords: cell carcinoma; renal cell; conditional survival; survival ... See more keywords
Pegilodecakin as monotherapy or in combination with anti‐PD‐1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Cancer"
DOI: 10.1002/ijc.33556
Abstract: Interleukin (IL)‐10 has anti‐inflammatory and CD8+ T‐cell‐stimulating properties. Pegilodecakin (pegylated recombinant human IL‐10) induces intratumoral antigen‐specific CD8 + T‐cells and upregulates IFNγ and major histocompatibility complexes (MHC) I and II. Pegilodecakin has single‐agent activity with manageable toxicity… read more here.
Keywords: renal cell; inhibitor; final results; advanced renal ... See more keywords
Milestones in advanced renal cell carcinoma
Sign Up to like & getrecommendations! Published in 2017 at "memo - Magazine of European Medical Oncology"
DOI: 10.1007/s12254-017-0321-9
Abstract: SummaryRenal cell carcinoma (RCC) is a common tumor that is largely refractory to cytotoxic agents. With the implementation of a multitude of novel therapies in the past 10 years, the overall survival of patients with advanced… read more here.
Keywords: renal cell; milestones advanced; cell carcinoma; advanced renal ... See more keywords
Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States
Sign Up to like & getrecommendations! Published in 2021 at "Advances in Therapy"
DOI: 10.1007/s12325-021-01926-0
Abstract: Nivolumab plus cabozantinib improved progression-free survival and overall survival compared with sunitinib in the first-line treatment of advanced renal cell carcinoma (RCC) according to CheckMate 9ER study. A Markov model was developed to compare the… read more here.
Keywords: first line; plus cabozantinib; nivolumab plus; advanced renal ... See more keywords
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Cell"
DOI: 10.1016/j.ccell.2021.02.015
Abstract: Summary Immune checkpoint blockade (ICB) results in durable disease control in a subset of patients with advanced renal cell carcinoma (RCC), but mechanisms driving resistance are poorly understood. We characterize the single-cell transcriptomes of cancer… read more here.
Keywords: immune; renal cell; cell carcinoma; cancer ... See more keywords
Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers.
Sign Up to like & getrecommendations! Published in 2020 at "Clinical genitourinary cancer"
DOI: 10.1016/j.clgc.2020.10.003
Abstract: BACKGROUND Nivolumab, a programmed death 1 inhibitor, has been approved as second-line treatment for advanced renal cell carcinoma (RCC) in Europe since 2016. We investigated the toxicity and efficacy of nivolumab as well as potential… read more here.
Keywords: treatment; efficacy; toxicity; toxicity efficacy ... See more keywords
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025.
Sign Up to like & getrecommendations! Published in 2017 at "European urology"
DOI: 10.1016/j.eururo.2017.03.037
Abstract: BACKGROUND Response patterns to nivolumab differ from those seen with other approved targeted therapies. OBJECTIVE To investigate the efficacy of nivolumab in previously treated patients with advanced renal cell carcinoma who were treated beyond (Response… read more here.
Keywords: renal cell; advanced renal; response; cell carcinoma ... See more keywords
Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma
Sign Up to like & getrecommendations! Published in 2017 at "British Journal of Cancer"
DOI: 10.1038/bjc.2017.206
Abstract: Background:In two clinical trials of the vascular endothelial growth factor (VEGF) receptor inhibitor pazopanib in advanced renal cell carcinoma (mRCC), we found interleukin-6 as predictive of pazopanib benefit. We evaluated the prognostic significance of candidate… read more here.
Keywords: advanced renal; cell carcinoma; renal cell; cytokines angiogenic ... See more keywords
Direct Oral Anticoagulants in the Treatment of Venous Thromboembolism: Use in Patients with Advanced Renal Impairment, Obesity, or Other Weight-Related Special Populations.
Sign Up to like & getrecommendations! Published in 2021 at "Seminars in respiratory and critical care medicine"
DOI: 10.1055/s-0041-1723952
Abstract: There are currently more than 7 million patients taking a direct oral anticoagulant (DOAC), with more new prescriptions per year than warfarin. Despite impressive efficacy and safety data for the treatment of venous thromboembolism, patients… read more here.
Keywords: use; obesity; advanced renal; renal impairment ... See more keywords
Combination therapy with checkpoint inhibitors for first-line treatment of advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz249.054
Abstract: Abstract Background Management of advanced renal cell carcinoma (RCC) is an area in dire need of therapeutic innovation. In recent years, combining immunotherapy with chemotherapy has shown synergistic anticancer activities and multiple randomized clinical trials… read more here.
Keywords: renal cell; checkpoint inhibitors; first line; checkpoint ... See more keywords